Today: 28 February 2026
Subscribe
Browse Category

Healthcare Innovation 16 October 2025 - 13 January 2026

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly shares rose 0.2% after the FDA asked drugmakers to remove suicide-related warnings from GLP-1 weight-loss drugs. Lilly’s R&D chief said the company plans a rapid global launch of its oral obesity drug orforglipron, priced at $150 a month. Investors are watching for increased pill competition and the FDA’s upcoming decision.
13 January 2026
···
Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Why Praxis Precision Medicines (PRAX) stock is down today after FDA breakthrough nod for its tremor drug

Praxis Precision Medicines shares fell 3% to $295.50 Tuesday afternoon, retreating after a 14% surge Monday on FDA Breakthrough Therapy Designation for ulixacaltamide in essential tremor. The company plans to submit a New Drug Application in early 2026. Jefferies and BTIG raised price targets following the FDA news.
30 December 2025
··
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical shares jumped 83% to $3.69 on December 4 after new data on its Emperor Total Artificial Heart was presented at ISMCS 2025 in Vienna. Trading volume soared to nearly 39 million shares. The company’s market cap reached $272 million, but the stock remains down over 70% from its October high of $13.68. After-hours trading showed some profit-taking, with prices around $3.30–$3.40.
5 December 2025
···
Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon (PLRZ) Stock Explodes on Naloxone Hydrogel Breakthrough and PL‑14 Upscaling – What Investors Should Know Now

Polyrizon shares surged over 100% to the mid-teens on December 4, 2025, with volume topping 26 million after announcing a manufacturing milestone for its PL‑14 Allergy Blocker and promising preclinical data for its naloxone hydrogel. The stock saw heavy volatility and mixed analyst signals, with “Strong Sell” ratings alongside momentum-driven “Buy” calls. The Israel-based biotech has no approved products.
4 December 2025
···
Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon (PLRZ) Stock Soars Over 130% on Nasal Spray Breakthrough: Is This Micro-Cap Biotech the Next Big Winner or a Speculative Trap?

Polyrizon Ltd. shares surged 131.96% on December 2, 2025, closing at $7.33 after announcing a key manufacturing milestone for its PL-14 nasal spray. Intraday trading saw prices swing between $5.85 and $8.36 on volume over 148 million shares. The Israeli biotech, still pre-commercial with no approved products or revenue, now holds a market cap near $14–15 million.
2 December 2025
·
AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie (ABBV) Stock in December 2025: Atogepant Breakthrough, Q3 Beat and 2026 Outlook After Medicare Price Cuts

AbbVie shares closed near $225 on December 1, 2025, valuing the company at about $400 billion. Q3 net revenue rose 9.1% to $15.78 billion, with adjusted EPS of $1.86 topping estimates. The company raised its 2025 profit forecast and approved a 5.5% dividend increase. Immunology sales climbed, while Humira revenue dropped below $1 billion.
1 December 2025
····
Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic (MDT) Soars as Q2 FY26 Earnings Beat Expectations and 2026 Outlook Is Raised on Pulsed Field Ablation Strength

Medtronic reported Q2 FY26 revenue of $8.96 billion, up 6.6% year over year, and non-GAAP EPS of $1.36, beating Wall Street estimates. Shares rose 4–5% intraday. Cardiac ablation revenue jumped 71% globally, with 128% growth in the U.S. The company raised its full-year outlook after its fourth straight quarter of beating consensus EPS.
18 November 2025
···
Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck to Buy Cidara Therapeutics for $9.2 Billion in Bold Bet on Long‑Acting Flu Prevention

Merck will acquire Cidara Therapeutics for about $9.2 billion, paying $221.50 per share in cash—a 109% premium to Cidara’s last close. The deal gives Merck rights to CD388, a Phase 3 long-acting flu prevention drug. Cidara shares doubled in pre-market trading. The transaction is expected to close in Q1 2026, pending approvals.
14 November 2025
···
Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health (OSCR) launches 2026 South Florida plans, adds ‘HelloMeno’; stock in focus — Nov. 10, 2025

Oscar Health announced new individual-market plans for Miami-Dade and four nearby South Florida counties, effective January 1, 2026, with enrollment via HealthCare.gov. The company also introduced HelloMeno, a menopause-focused plan with Elektra Health, available in multiple states for 2026. Managed-care stocks fell after Trump criticized ACA subsidies, pressuring marketplace insurers.
10 November 2025
··
Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

Telehealth Trailblazer VSee Health (VSEE) Skyrockets on Game-Changing Deals & Federal Green Light

VSee Health secured a three-year contract to deploy virtual urgent care at over 100 facilities for a major U.S. academic health system, starting January 2026. On Oct. 28, 2025, its telehealth platform received FedRAMP High Authorization, enabling federal agency use. Shares surged from $0.45 to over $1.00 after the news. Q2 2025 revenue nearly doubled to $3.4 million, but the company remains unprofitable.
4 November 2025
·
Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers Bets Big on “GLP-1 Microdosing” Weight-Loss Trend – Stock and Experts React

Hims & Hers said Oct. 29 it will offer clinician-supervised GLP-1 “microdose” plans using compounded semaglutide for metabolic health, priced at $1,200 for six months. The drugs, not FDA-approved, target patients with conditions like sleep apnea or high blood pressure. Medical experts warn safety data is limited and compounded versions carry risks. HIMS stock rose 2–3% after the announcement.
3 November 2025
···
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet?

Acrivon Therapeutics shares jumped about 14% pre-market Nov. 3, 2025, trading near $2.27, down roughly 85% from its $12.50 IPO in 2022. Interim Phase 2b data for lead drug ACR-368 showed a 35% response rate in advanced endometrial cancer. The FDA granted Fast Track status to ACR-368 and Breakthrough Device designation to its companion diagnostic. Acrivon employs around 78 people in Watertown, MA.
3 November 2025
··
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Rockets 51% on Obesity Pill Breakthrough and $1B Pharma Deal

Rani Therapeutics shares closed at $2.20 on Oct. 31, up 51.7% for the day, following a $1.09 billion collaboration deal with Chugai Pharma and a $60.3 million equity raise. Trading volume surged, with nearly 172 million shares changing hands Oct. 20. Founder Mir Imran bought 2.08 million shares Oct. 27. Wall Street analysts now rate RANI a “Strong Buy” with average price targets near $10–11.
31 October 2025
··
From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

From Cannabis Clinics to Bitcoin Billions: KindlyMD (NAKA) Stock’s Wild 2025 Ride

KindlyMD (NASDAQ: NAKA) shares soared 650% to $29 after merging with Bitcoin holding firm Nakamoto Holdings in August 2025, then crashed 96% to $0.65 amid dilution fears. The company raised $710 million to buy 5,744 BTC and filed for up to $5 billion in new stock sales. Recent loans and partnerships aim to refinance debt. Analysts remain split as NAKA trades near $1, with weak earnings and high volatility.
28 October 2025
····
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Over 62,000 pharmaceutical professionals from more than 170 countries are attending CPHI Frankfurt 2025, where executives are meeting to address global supply chain, regulation, and innovation challenges. Eli Lilly’s GLP-1 drugs generated $6.1 billion in Q1 2025, overtaking Novo Nordisk in the U.S. weight-loss drug market. Pharma giants are investing heavily as the global obesity treatment market is projected to reach $100 billion by 2030.
28 October 2025
····
CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics shares traded near $69 in mid-October after rising about 40–45% over the past year. The company plans to raise up to $600 million in a new share offering announced October 15. Bank of America raised its price target to $93 and maintained a Buy rating. CRISPR reported preclinical success for CTX460 and continues to expand Casgevy’s commercial reach.
19 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL shares surged 13–14% to a record $85.35 on Oct. 16 after announcing a $110 million equity deal with Samsung and plans to bring its Galleri cancer test to Asia. New trial data at ESMO showed Galleri doubled early cancer detection versus routine screening. Despite gains, most analysts rate GRAL a “Hold” with an average target below current prices. Q2 revenue rose 11% to $35.5M; net loss narrowed to $114M.
18 October 2025
···
Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (FEMY) Stock Soars 46% on Fertility Tech and FDA Milestones

Femasys (NASDAQ: FEMY) jumped 46% to $0.80 by mid-day Oct. 16 after announcing its FemaSeed fertility treatment will be showcased at ASRM 2025. The company recently secured European, UK, and New Zealand approvals for its FemBloc birth control device and reported its first European sales and new distribution deals. Q2 revenue rose 85% year-over-year to $0.409 million.
16 October 2025
··
1 2
Go toTop